Fast Facts

Company Overview

Depomed, Inc. (Nasdaq DEPO) is a specialty pharmaceutical company with two products on the market and multiple product candidates in its pipeline.

The company utilizes its proven, proprietary Acuform™ delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Glumetza® (metformin HCl extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in Canada by Biovail Corporation. Proquin® XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed to urologists, Ob/Gyn, and long-term care physicians by Watson Pharmaceuticals. Product candidate Gabapentin GR® is currently in advanced clinical development for the treatment of menopausal hot flashes.

Recent EVents 

• Proquin XR approved in Sweden
• Depomed receives grant from The Michael J. Fox Foundation for development of levodopa/carbidopa in Parkinson's Disease
• Santarus, Inc. to promote Glumetza in the U.S.